Table 2

Results of longitudinal analyses comparing SIGLEC1 and CK with disease activity scores (CMAS/PGA) for (A) 12 juvenile and (B) 14 adult dermatomyositis patients

A: Patients with juvenile dermatomyositis
Do SIGLEC1/CK correlate with CMAS over time?
CMAS—all values*n=65
betaST=−0.70; p<0.001
95% CI −0.85 to −0.54
n=87
betaST=−0.39; p<0.001
95% CI −0.57 to −0.21
CMAS—visits with complete data (SIGLEC1 and CK)†n=53
betaST=−0.65; p<0.001
95% CI −0.80 to −0.49
n=53
betaST=−0.50; p<0.001
95% CI −0.66 to −0.33
Is the change of SIGLEC1/CK associated with a change in CMAS?
Change between visits (∆ Visitt-1 and visitt):
CMAS—all values*n=28
betaST=−0.53; p<0.001
95% CI −0.77 to −0.29
n=41
betaST=−0.27; p=0.051
95% CI −0.62 to –0.08
CMAS—visits with complete data (SIGLEC1 and CK)†n=16
betaST=−0.42; p<0.001
95% CI −0.71 to −0.14
n=16
betaST=−0.14; p=0.566
95% CI −0.39 to 0.11
B: Patients with adult dermatomyositis
Do SIGLEC1/CK correlate with PGA over time?
PGA—all values*n=45
betaST=0.54; p<0.001
95% CI 0.34 to 0.74
n=41
betaST=0.17; p=0.149
95% CI −0.11 to 0.45
PGA—visits with complete data (SIGLEC1 and CK)†n=41
betaST=0.52; p<0.001
95% CI 0.32 to 0.72
n=41
betaST=0.17; p=0.149
95% CI −0.11 to 0.45
Is the change of SIGLEC1/CK associated with a change in PGA?
Change between visits (∆ visitt-1 and visitt):
PGA—all values*n=31
betaST=0.48; p=0.003
95% CI 0.16 to 0.79
n=25
betaST=0.10; p=0.634
95% CI −0.45 to 0.27
PGA—visits with complete data (SIGLEC1 and CK)†n=25
betaST=0.60; p=0.001
95% CI 0.29 to 0.91
n=25
betaST=−0.10; p=0.634
95% CI −0.45 to 0.27
  • Statistical analysis was performed using a two-level mixed-effects linear regression model.

  • *SIGLEC1 and CK values were analysed independently of each other.

  • †Included only those visits where both biomarkers (SIGLEC1 and CK) were assessed (complete-case analysis).

  • betaST, standardised beta coefficient; CK, creatine kinase; CMAS, Childhood Myositis Assessment Scale; n, number of analysed values; PGA, Physician Global Assessment; SIGLEC1, sialic acid binding Ig-like lectin 1.